Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism

Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism Primary efficacy endpoint achieved based on preliminary results from a November 5 th data evaluation Topline results for the completed study, along with additional study detail

Event · Clinical / regulatory
Product
ersodetug
Milestone
topline data
Indication
tumor hyperinsulinism

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 13, 2026, 11:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 11:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RZLT
Bullish
high confidence
Mentioned
$RZLT
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RZLTBullishHigh
01

Why it matters

Positive Phase 3 data could accelerate FDA discussions and increase valuation.

02

Market read

First disclosure of pivotal trial success; likely catalyst for stock movement.

03

What to watch

Regulatory timeline and potential competition in hyperinsulinism therapies.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Rezolute focuses on refractory hypoglycemia caused by hyperinsulinism; ersodetug is its investigational antibody.

Company-level read

Ticker impact

$RZLTBullishHigh confidence
Context

Rezolute disclosed positive Phase 3 upLIFT trial results, achieving primary efficacy endpoint.

Expected impact

upward pressure as market prices in efficacy success

Evidence & confidence

First report of pivotal trial success for a late‑stage biotech, material for valuation.

Market effects

Boosts confidence in ultra‑rare metabolic disease space and similar biotech pipelines.

May lift US biotech sector sentiment.

Limited to biotech investors, no broad market effect.

Counterpoint

Trial size is small (16 patients); results may not translate to larger studies.

Key entities

  • Rezolute, Inc.

    Late‑stage biotech developing ersodetug.

  • Nevan Charles Elam

    Founder and CEO of Rezolute.

Related articles

$RZLTMed

Wedbush raises Rezolute stock price target on tumor trial data

Wedbush raised its price target for Rezolute Inc. (RZLT) to $10 from $6, citing positive Phase 3 trial data. The new target suggests 179% upside from the current $3.58 share price. The firm increased its success probability for hyperinsulinism treatments and adjusted its revenue forecasts. Rezolute recently completed enrollment in a Phase 3 study and has strong liquidity, according to InvestingPro.

$RZLTHighAI 8/10

Why is Rezolute stock surging today?

Rezolute's stock rose 7.8% pre-market after reporting positive Phase 3 trial results for ersodetug and a $100M equity offering at $3.87/share. The trial met its primary endpoint, with 13 of 16 participants reducing IV glucose needs. The offering, led by Frazier Life Sciences, is expected to close by November 16. The company plans FDA discussions for both indications in Q1 2027.